Skip to content
‹ Back to IndustriesHealthcare

Biotech Moves Smarter: IDDI Powers Data-Driven Drug Innovation

This episode of 'While You Were Working' features Chip Rosales interviewing Jeremy Edwards, Chief Commercial Officer at IDDI, about how the specialized CRO helps small and mid-size biotech companies navigate clinical trial design and regulatory pathways. The conversation covers IDDI's differentiation in a crowded CRO market, its spin-off 'One to Treat,' and how AI and innovative statistical methods are shaping the future of clinical research. Edwards also discusses his strategic priorities for expanding IDDI's U.S. brand presence.

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Promoted content from Rogue Marketing on MarketScale.

By Chip Rosales · · Artificial Intelligence (ai)Biotech CompaniesBiotech InnovationClinical Trials
Share

Key takeaways

01

IDDI provides personalized, hands-on clinical trial design and data support tailored to small and mid-size biotech companies that may be deprioritized by larger CROs.

02

IDDI's spin-off 'One to Treat' pioneers multi-endpoint trial design to capture richer, patient-centered outcomes in oncology and rare diseases.

03

Jeremy Edwards is focused on building U.S. brand awareness for IDDI and introducing differentiated messaging in a traditionally conservative industry.

Free workspace

Turn your Healthcare expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

As biotech innovation accelerates, small and mid-size pharmaceutical companies are becoming key players in bringing new treatments to market. Yet many of these organizations face steep challenges when navigating clinical trial design, regulatory approval, and data integrity. According to a McKinsey Global Institute report, industries like biotech could help generate up to $50 trillion in global revenue by 2040, underscoring their massive economic and social impact.

Industries like biotech could help generate up to $50 trillion in global revenue by 2040, underscoring their massive economic and social impact.

So how can niche research partners like IDDI help smaller biotech companies overcome these hurdles and compete in a market dominated by major pharmaceutical brands?

In this episode of While You Were Working, host Chip Rosales, Managing Partner at Rogue Marketing, speaks with Jeremy Edwards, Chief Commercial Officer at IDDI. The conversation explores how Edwards is helping IDDI expand its U.S. footprint, how the company differentiates itself in a saturated CRO market, and what innovations like AI and creative trial design mean for the future of clinical research.

Key Highlights from the Conversation:

  • Supporting Small Biotech Companies: IDDI specializes in providing hands-on, personalized trial design and data support for small and mid-size biotech firms, helping them avoid getting lost among larger CRO priorities.
  • Creative Statistical Methods & Innovation: With its spin-off "One to Treat," IDDI is pioneering multi-endpoint trial design to capture richer, more patient-centered outcomes in areas like oncology and rare diseases.
  • Market Expansion & Differentiation: Edwards' top priorities include building U.S. brand awareness, leveraging therapeutic area expertise, and introducing differentiated messaging in a traditionally conservative industry. Edwards' top priorities include building U.S. brand awareness, leveraging therapeutic area expertise, and introducing differentiated messaging in a traditionally conservative industry.

Jeremy Edwards is a seasoned executive in clinical research and digital health, with over two decades of experience leading commercial strategy, business development, and international expansion for CROs and biotech service organizations. He currently serves as Chief Commercial Officer at IDDI, where he focuses on clinical trial design innovation and expanding the company's U.S. presence. Previously, Edwards held senior leadership roles at YPrime, Xperiome, and AMRA Medical, consistently driving growth through strategic partnerships, rare disease expertise, and technology-enabled patient engagement.

Rogue Marketing

Part of this channel

Rogue Marketing

B2B marketing strategy from practitioners who do the work.

Visit the channel

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

CR
Chip RosalesManaging Partner

For nearly 20 years, Chip has been bending the rules, asking the question “why” and looking for innovative ways to get companies noticed. This has led to a number of corporate executive roles with opportunities to lead digital marketing teams, uncover emotional differentiators and build/amplify brands. In 2009, he left corporate America to build a strategy agency of his own. You can find Chip keepin’ it Rogue performing on stages around the Dallas metroplex and rooting on the UT Longhorns… whether they’re winning or not.

B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Healthcare Insights

Advocate Health's Hugh Chatham draws 65 applicants for 12 surgical tech seats

Advocate Health's Hugh Chatham draws 65 applicants for 12 surgical tech seats

Hugh Chatham Health and Alleghany Health marked one year inside Advocate Health with a surgical technology program that drew 65 applicants for 12 seats. Year one also brought $11.3 million in pay and rewards, $19.3 million in capital and nearly 1,000 specialty transfers. Local training seats look like the next limit in Elkin.

  • 01In rural North Carolina, a new surgical technology program drew more than five applicants per seat, which points to training capacity, not interest, as the thing to expand.
  • 02Pay spending in the first year of a rural affiliation came to roughly 58% of the capital figure: $11.3 million in total rewards next to $19.3 million in capital.
  • 03Transfers outnumbered virtual specialty consults about 14 to 1 in year one, so the planned growth in virtual care is the year-two number worth tracking.

Nov 10, 2026

AI cuts cardiologists' echocardiogram review time by 46%

AI cuts cardiologists' echocardiogram review time by 46%

Late-breaking research presented November 9 at the American Heart Association's Scientific Sessions 2026 reported that AI-drafted preliminary echocardiogram reports were comparable to human drafts. Cardiologists averaged 4.6 minutes finalizing AI drafts versus 8.5 minutes without AI. The findings are a non-peer-reviewed abstract.

  • 01Cardiologists averaged 4.6 minutes finalizing AI-drafted echo reports versus 8.5 minutes without AI, about 46% less time.
  • 02Cardiologists made substantial changes to 50.6% of AI drafts and 49.7% of human drafts.
  • 03The research used 1,200 echocardiograms from 21 Kaiser Permanente Northern California medical centers.

Nov 9, 2026

After Chicago: Did AI at AHA 2026 Pass Its Own Test?

After Chicago: Did AI at AHA 2026 Pass Its Own Test?

At AHA Scientific Sessions 2026 in Chicago, AI ECHO INSIGHT, WATCH-LV, PARAMOUNT and PROVAR+ showed gains in workflow efficiency, screening and treatment decisions, but none established a reduction in hard clinical events. The takeaway: the next test is proving these tools improve outcomes, especially in high-need populations, by connecting to established care.

  • 01AI ECHO INSIGHT cut echo reads 8.5 to 4.6 minutes, and PARAMOUNT changed treatment decisions, but no AI late-breaker showed fewer hard events.
  • 02ZEUS and Lp(a)HORIZON lowered their target biomarkers without reducing major cardiovascular events, a caution against treating algorithmic accuracy alone as proof of patient benefit.
  • 03Low-technology, team-based interventions such as CATCH in Colombia and Jamaica lowered blood pressure, showing the care systems AI tools must connect to.

Nov 9, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

About the Experts

CR
Chip Rosales

Managing Partner at Rogue Marketing

Chip Rosales is Managing Partner at Rogue Marketing, a creative and strategic marketing agency focused on helping businesses stand out and drive measurable growth. He hosts the podcast series 'While You Were Working,' where he speaks with business and industry leaders about innovation and market strategy. Rosales brings a background in brand development and marketing communications to his work with clients across multiple industries.

JE
Jeremy Edwards

Chief Commercial Officer

IDDI

Jeremy Edwards is a seasoned executive in clinical research and digital health with over two decades of experience leading commercial strategy, business development, and international expansion for CROs and biotech service organizations. He currently serves as Chief Commercial Officer at IDDI, where he focuses on clinical trial design innovation and expanding the company's U.S. presence. Previously, he held senior leadership roles at YPrime, Xperiome, and AMRA Medical.

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512